Ash Publications

International

English

Media Company

Outlet metrics

Domain Authority

Ranking

Global

#73355

United States

#31979

Health/Medicine

#336

Traffic sources

Monthly visitors

Articles

A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia

Jun 13, 2024 | ashpublications.org | Karl Landsteiner

Subjects: , Immunobiology and Immunotherapy, Lymphoid Neoplasia Subjects: , Immunobiology and Immunotherapy, Lymphoid Neoplasia Subjects: , Immunobiology and Immunotherapy, Lymphoid Neoplasia Natural killer (NK)-cell malignancies are rare types of cancer that originate from the abnormal growth and proliferation of NK cells. They can be aggressive and challenging to treat.
Long noncoding RNA GATA2AS influences human erythropoiesis by transcription factor and chromatin landscape modulation

May 30, 2024 | ashpublications.org | Kidney Diseases

Long noncoding RNAs (lncRNAs) are extensively expressed in eukaryotic cells and have been revealed to be important for regulating cell differentiation. Many lncRNAs have been found to regulate erythroid differentiation in the mouse. However, given the low sequence conservation of lncRNAs between mouse and human, our understanding of lncRNAs in human erythroid differentiation remains incomplete. lncRNAs are often transcribed opposite to protein coding genes and regulate their expression.
Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

May 30, 2024 | ashpublications.org | Yale College

We evaluated the cost-effectiveness of prophylaxis with recombinant von Willebrand factor (rVWF) vs with plasma-derived von Willebrand factor (pdVWF) for patients with severe Von Willebrand disease. We found that rVWF is a cost-saving factor replacement compared with pdVWF across all willingness-to-pay thresholds in the United States.
Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children

May 30, 2024 | ashpublications.org | Blood Disorders

Citation Carolin S. EscherichWenan ChenYizhen LiWenjian YangRina NishiiZhenhua LiElizabeth A. RaetzMeenakshi DevidasGang WuKim E. NicholsHiroto InabaChing-Hon PuiSima JehaBruce M. CamittaEric LarsenStephen P. HungerMignon L. LohJun J. Yang; Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children. Blood 2024; 143 (22): 2270–2283.
Results Encouraging for Glofitamab in CNS Involvement in B-Cell Lymphoma

May 29, 2024 | ashpublications.org | Ruth Jessen Hickman

The U.S. Food and Drug Administration’s (FDA) recent approvals of the bispecific CD20xCD3 antibodies mosunetuzumab, epcoritamab, and glofitamab have substantially improved prospects for patients with systemic diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, but their utility in treating central nervous system (CNS) lymphoma remains unknown.
Study Explores Endothelial Mechanisms of Hydroxyurea’s Stroke Prevention in SCA

May 29, 2024 | ashpublications.org | Ruth Jessen Hickman

A study published in Blood Vessels, Thrombosis & Hemostasis suggests potential causative links between the endothelial activator angiopoietin-2 and complications of stroke from sickle cell anemia (SCA), effects that may be partially ameliorated through hydroxyurea treatment.1 The disease-modifying agent hydroxyurea is part of standard-of-care treatment for SCA in the U.S., with guidelines from the National Heart, Lung, and Blood Institute recommending that therapy be initiated as early as 9...
Venous and arterial thrombosis in patients with VEXAS syndrome

May 23, 2024 | ashpublications.org | Skin Diseases

Citation Yael KusneAtefeh GhorbanzadehAlina Dulau-FloreaRuba ShalhoubPedro E. AlcedoKhanh NghiemMarcela A. FerradaAlexander HinesKaitlin A. QuinnSumith R. PanickerAmanda K. OmbrelloKaaren ReichardIvana DardenWendy GoodspeedJibran DurraniLorena WilsonHoratiu OlteanuTerra LashoDaniel L. KastnerKenneth J. WarringtonAbhishek MangaonkarRonald S. GoRaul C. BraylanDavid B. BeckMrinal M. PatnaikNeal S. YoungKatherine R. CalvoAna I. CasanegraPeter C. GraysonMatthew J. KosterColin O. WuYogendra KanthiBhavisha A.
Giving T-cell bispecifics a helping hand

May 23, 2024 | ashpublications.org | Ludwig Maximilian |Helmholtz Zentrum München

Subjects: In this issue of Blood, Sam et al demonstrate the translational potential of CD19-targeted CD28-mediated costimulation to ameliorate the therapeutic potential of the anti-CD19–anti-CD3 T-cell bispecific engager glofitamab in preclinical models, buttressing the rationale for an ongoing phase 1 clinical study.1 T cells are inherently specific for a single antigen presented in the context of major histocompatibility complex (MHC).
FAIR WARNING?

May 21, 2024 | ashpublications.org | Emma Yasinski

As of late January, 22 of 34,400 patients being treated with chimeric antigen receptor (CAR) T-cell therapy for certain blood cancers had developed a secondary T-cell malignancy.1 As a result, the U.S. Food and Drug Administration (FDA) directed the manufacturers of six CAR T-cell treatments to include a black box warning to alert patients and physicians to the drug’s potential cancer risk.2,3 However, the FDA has acknowledged that the benefits of CAR T-cell treatment continue to outweigh the...
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

May 17, 2024 | ashpublications.org | Johns Hopkins |Daniel Howard |Gustave Roussy

This content is only available as a PDF. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.